Medpace Holdings Inc. (MEDP)
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace (MEDP) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Medpace (MEDP) closed at $405.33, marking a -0.53% move from the previous day.
Medpace (MEDP) Advances But Underperforms Market: Key Facts
Medpace (MEDP) closed the most recent trading day at $395.95, moving +0.52% from the previous trading session.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
The latest trading day saw Medpace (MEDP) settling at $405.68, representing a +1.12% change from its previous close.
Medpace: Clear Winner If China Blockade Succeeds
Medpace Holdings is a US-based clinical research organization that is well-positioned to benefit from increased demand due to geopolitical risks affecting Chinese firms. Medpace stands out among its peers due to its growth orientation, competitive margins, and focus on next-generation therapies. While Medpace lacks diversification compared to WuXi Biologics, a pair trade strategy can help reduce risk and take advantage of the opportunities in the healthcare market.
Here is Why Growth Investors Should Buy Medpace (MEDP) Now
Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Medpace (MEDP) Rises Higher Than Market: Key Facts
The latest trading day saw Medpace (MEDP) settling at $390.81, representing a +0.07% change from its previous close.
Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Beacon Pointe Advisors LLC
Beacon Pointe Advisors LLC lifted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 21.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,514 shares of the company’s stock after acquiring an additional 979 shares during the quarter. Beacon Pointe Advisors LLC’s holdings in Medpace were worth $1,690,000 as of its most recent filing with the Securities and Exchange Commission. Other hedge funds and other institutional investors have also made changes to their positions in the company. RiverPark Advisors LLC acquired a new stake in Medpace during the 4th quarter valued at $26,000. Contravisory Investment Management Inc. acquired a new stake in shares of Medpace during the 4th quarter worth approximately $26,000. GAMMA Investing LLC acquired a new stake in shares of Medpace during the 4th quarter worth approximately $30,000. McGlone Suttner Wealth Management Inc. acquired a new position in Medpace during the 4th quarter valued at approximately $33,000. Finally, Principal Securities Inc. bought a new position in Medpace during the 4th quarter worth $68,000. Institutional investors and hedge funds own 77.98% of the company’s stock. Insiders Place Their Bets In other news, VP Susan E. Burwig sold 102 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the sale, the vice president now directly owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction on Friday, March 15th. The stock was sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the company’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 159,224 shares of company stock worth $65,030,941. 20.30% of the stock is currently owned by company insiders. Wall Street Analysts Forecast Growth Several brokerages recently weighed in on MEDP. Guggenheim lifted their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Robert W. Baird boosted their price target on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their price target for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $443.00. Read Our Latest Report on Medpace Medpace Trading Up 0.0 % NASDAQ MEDP opened at $393.30 on Monday. Medpace Holdings, Inc. has a 1 year low of $197.39 and a 1 year high of $421.00. The stock’s 50-day moving average price is $396.43 and its two-hundred day moving average price is $342.35. The company has a market cap of $12.18 billion, a PE ratio of 40.09, a PEG ratio of 1.95 and a beta of 1.40. Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to analysts’ expectations of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.27 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 11.29 EPS for the current fiscal year. Medpace Company Profile (Free Report) Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
